Clinical trial · Observational
Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis
NCT02401763CI-TRIAL-00017372unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nasopharyngeal carcinoma (NPC) is the tenth leading cancers in Taiwan and investigating its biomarker is important for understanding the mechanism of its pathogenesis.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Salivary Gland Cancer | Malignant Salivary Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Nasopharyngeal carcinoma and salivary gland tumor
- description
- patients diagnosed and treated in National Taiwan University Hospital
Primary outcomes (1)
- measure
- The difference of expression level of mucin glycosylating enzymes (by immunohistochemistry) in nasopharyngeal carcinoma and salivary gland tissues
- timeFrame
- 1~5 years after patients received definite therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * NPC and salivary gland tumor diagnosed and treated in HTUH Exclusion Criteria: * previous treatment or surgery
References
Publications (0)
Data not yet available
No reference posted for this study.